2-Diphenylmethylpyrrolidine (Desoxy-D2PM), also known as 2-benzhydrylpyrrolidine, is a stimulantpsychoactive drug. It is the 4-dehydroxylated structural analog of diphenylprolinol (D2PM), and is also similar in structure to desoxypipradrol (2-DPMP), both of which act as norepinephrine-dopamine reuptake inhibitors (NDRIs). Like D2PM and 2-DPMP, Desoxy-D2PM is sold as a designer drug and has been used in the manufacture of legal highs. It has been marketed under the names A3A New Generation, A3A Methano, and Green Powder, and has been reported to cause hallucinations, violent behavior, dilated pupils, tachycardia, and high blood pressure.[1][2][3] Literature data suggest that it can produce the same psychotropic effects as other stimulants, but with a longer duration of action.[4]
As of 4 November 2010, the UKHome Office announced a ban on the importation of 2-diphenylmethylpyrrolidine, following a recommendation from the ACMD.[6] It was due to become a class B drug[7] on 28 March 2012,[8] but the bill was scrapped, due to the presence of two steroids included in the bill that were later recommended to remain uncontrolled.[9]
It was made a class B drug and placed in Schedule I on 13 June 2012.[10]
References
^De Paoli G, Brandt SD, Pounder DJ (December 2011). "Analytical characterization and rapid determination of 2-(diphenylmethyl)pyrrolidine in blood and application to an internet product". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879 (31): 3771–4. doi:10.1016/j.jchromb.2011.10.014. PMID22055832.
^Coppola M, Mondola R (July 2012). "Research chemicals marketed as legal highs: the case of pipradrol derivatives". Toxicology Letters. 212 (1): 57–60. doi:10.1016/j.toxlet.2012.04.019. PMID22564760.
^Bertelsen S, Halland N, Bachmann S, Marigo M, Braunton A, Jørgensen KA (October 2005). "Organocatalytic asymmetric alpha-bromination of aldehydes and ketones". Chemical Communications (38): 4821–3. doi:10.1039/b509366j. PMID16193126.